By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Revotar Biopharmaceuticals AG 

Neuendorfstr. 24a

D-16761 Hennigsdorf       Germany
Phone: 3302-2025010 Fax: 3302-2025030


Company News
Revotar Biopharmaceuticals Receives New Composition-of-Matter Patent for Bimosiamose in the US 11/2/2011 9:29:14 AM
Revotar Biopharmaceuticals Positive Multi-Center COPD Trial with Inhaled Bimosiamose to be Presented at the European Respiratory Society Annual Congress 2011 in Amsterdam 9/21/2011 6:50:19 AM
Revotar Biopharmaceuticals Presents Significant Final Results from 4 Weeks Phase II COPD Study 5/19/2011 8:46:46 AM
Revotar Biopharmaceuticals Meets Primary Endpoint in Phase II COPD Study with Inhaled Bimosiamose 3/4/2011 7:09:27 AM
Revotar Biopharmaceuticals Starts Phase II Clinical Trial in COPD Patients with Inhaled Bimosiamose 6/10/2010 11:18:39 AM
Revotar Biopharmaceuticals Presents Positive Results In Phase IIa Ozone Study With Bimosiamose For COPD 5/18/2010 12:09:20 PM
Revotar Biopharmaceuticals Announces the Appointment of Ludwig Felber as Chief Financial Officer and Member of the Executive Board and the Election of Prof Dr Wolfgang Hartwig as New Supervisory Board Member 6/3/2009 2:37:29 PM
Revotar Biopharmaceuticals Starts Phase II Clinical Trial in Psoriasis with its Bimosiamose 5% Cream 2/2/2009 3:09:16 PM
Revotar Biopharmaceuticals Reports Positive Preclinical Data From A 4-Month Dermal Toxicity Study 10/29/2008 11:49:45 AM
Revotar Biopharmaceuticals Reports Positive Phase I Data In Psoriasis With Its Bimosiamose 5% Cream 10/13/2008 2:23:09 PM